Evidence map›Paper›PMID 41294700›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.

Patricio M Polanco, Tamas Gonda, Erkut Borazanci, Evan S Glazer, Jose G Trevino, George DeMuth, Lisa Ford, Thomas King, Norma A Palma, Randall E Brand

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Patricio M PolancoDivision of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Tamas GondaDivision of Gastroenterology & Hepatology, New York University, New York, NY 10016, USA.
Erkut BorazanciDepartment of Oncology, HonorHealth Research Institute, Scottsdale, AZ 10510, USA.ORCID 0000-0001-5136-5462
Evan S GlazerDivision of Surgical Oncology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-5796-0542
Jose G TrevinoDivision of Surgical Oncology, School of Medicine and Surgeons, Virginia Commonwealth University, Richmond, VA 23298, USA.
George DeMuthStat One, LLC, Morrisville, NC 27560, USA.ORCID 0000-0002-9249-9843
Lisa FordImmunovia, Inc., Durham, NC 27713, USA.ORCID 0000-0002-6207-8108
Thomas KingImmunovia, Inc., Durham, NC 27713, USA.ORCID 0009-0006-8581-5824
Norma A PalmaImmunovia, Inc., Durham, NC 27713, USA.ORCID 0000-0001-6900-0533
Randall E BrandDivision of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA.ORCID 0000-0002-4136-3313

Funding

Validation of biomarkers for risk prediction and early diagnosis of Pancreatic AdenocarcinomaU01CA200466 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Surinder K. Batra, Randall Brand · 2016 to 2026
$11.3M
Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesionsU01CA274514 · NCI · JOHNS HOPKINS UNIVERSITY · PI Randall Brand, DANIEL Wanyui CHAN · 2023 to 2026
$3.2M
NCI NIH HHS U01 CA200466NCI NIH HHS U01 CA274514NIH/NCI UO1 CA200466NIH/NCI UO1 CA274514
6 · The paper itself

Abstract

Early detection of pancreatic ductal adenocarcinoma (PDAC) could extend patient survival, and biomarkers to facilitate this are urgently needed. Here, we performed a second independent validation of PancreaSure, a 5-plex serum biomarker signature to detect early-stage PDAC in high-risk individuals. In contrast to the first validation, this study's cohort was preemptively balanced for age and sex and only included samples stored for fewer than 5 years. The primary endpoint was to measure test sensitivity against the performance target of 65%. Measuring specificity against the performance target of 90% and comparing test performance to that of carbohydrate antigen 19-9 (CA 19-9) alone were secondary endpoints. Signature analytes were retrospectively measured in serum from a blinded independent cohort of Stage I and II PDAC cases and high-risk controls. A predictive signal for PDAC was generated from a predefined cutoff established in a previous model development study. PancreaSure distinguished early-stage PDAC from controls with 76.5% sensitivity (95% CI, 67.7-83.9), significantly higher than the performance target (

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAgedCA-19-9 AntigenEarly Detection of CancerFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesBiomarkers, TumorCA-19-9 Antigenbiomarkersearly detectionhigh-riskmucinous pancreatic cystpancreatic ductal adenocarcinomapathogenic germline mutation

Identifiers

PMID41294700
PMCPMC12651218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.